|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:cabozantinib
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:ATCCode
|
L01XE26
|
|
gptkbp:contraindication
|
hypersensitivity to cabozantinib
|
|
gptkbp:developedBy
|
gptkb:Exelixis
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:eliminationHalfLife
|
99 hours
|
|
gptkbp:EMA_approval_year
|
2016
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cabometyx
|
|
gptkbp:indication
|
hepatocellular carcinoma
renal cell carcinoma
medullary thyroid cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:Ipsen
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:prescriptionRequired
|
https://www.cabometyx.com/
|
|
gptkbp:proteinBinding
|
high (>99%)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:palmar-plantar_erythrodysesthesia
nausea
diarrhea
fatigue
hypertension
decreased appetite
|
|
gptkbp:bfsParent
|
gptkb:cabozantinib
|
|
gptkbp:bfsLayer
|
6
|